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Abstract
Background: Respiratory syncytial virus (RSV) is the most common cause of acute bronchiolitis
in infants and the elderly. Furthermore, epidemiological data suggest that RSV infection during
infancy is a potent trigger of subsequent wheeze and asthma development. However, the
mechanism by which RSV contributes to asthma is complex and remains largely unknown. A recent
study indicates that the age of initial RSV infection is a key factor in determining airway response
to RSV rechallenge. We hypothesized that severe RSV infection during neonatal development
significantly alters lung structure and the pulmonary immune micro-environment; and thus,
neonatal RSV infection is crucial in the development of or predisposition to allergic inflammatory
diseases such as asthma.
Methods: To investigate this hypothesis the present study was conducted in a neonatal mouse
model of RSV-induced pulmonary inflammation and airway dysfunction. Seven-day-old mice were
infected with RSV (2 × 105 TCID50/g body weight) and allowed to mature to adulthood. To
determine if neonatal RSV infection predisposed adult animals to enhanced pathophysiological
responses to allergens, these mice were then sensitized and challenged with ovalbumin. Various
endpoints including lung function, histopathology, cytokine production, and cellularity in
bronchoalveolar lavage were examined.
Results: RSV infection in neonates alone led to inflammatory airway disease characterized by
airway hyperreactivity, peribronchial and perivascular inflammation, and subepithelial fibrosis in
adults. If early RSV infection was followed by allergen exposure, this pulmonary phenotype was
exacerbated. The initial response to neonatal RSV infection resulted in increased TNF-α levels in
bronchoalveolar lavage. Interestingly, increased levels of IL-13 and mucus hyperproduction were
observed almost three months after the initial infection with RSV.
Conclusion:  Neonatal RSV exposure results in long term pulmonary inflammation and
exacerbates allergic airways disease. The early increase in TNF-α in the bronchoalveolar lavage
implicates this inflammatory cytokine in orchestrating these events. Finally, the data presented
emphasize IL-13 and TNF-α as potential therapeutic targets for treating RSV induced-asthma.
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Background
Respiratory syncytial virus (RSV) is the most common
cause of upper and subsequent lower respiratory tract
infection in children and the elderly and is most severe in
children between the ages of 8 and 30 weeks [1]. Severe
RSV infection occurs in 1–2% of the cases and may result
in acute bronchiolitis that requires mechanical ventila-
tion. [2].
Several studies have suggested that severe RSV lower respi-
ratory tract infection in infancy may induce later develop-
ment of asthma [3-8]. In 2000, Sigur and colleagues
reported that RSV infection in infancy, severe enough to
require hospitalization, was associated with asthma and
allergy in children up to age 7 [9]. More recently, they
reported that the relationship between severe RSV bron-
chiolitis in infancy and later development of asthma and
allergy sensitization are still observed in children up to
age 13. [10]. In murine models, numerous studies have
been carried out and controversial results have been
reported. While some studies propose that previous RSV
infection enhances allergen sensitization and exacerbates
asthma, others believe that RSV infection in infancy pro-
tects against later allergic sensitization [11]. This contro-
versy is now thought to arise from the age of initial RSV
infection and the different protocols used for RSV infec-
tion and allergen sensitization and challenge. In two inde-
pendent experiments, researchers suggested that the
timing of primary RSV infection is significant for predict-
ing disease outcome. Culley and colleagues reported that
if neonatal mice (1 d or 7 d of age) were infected with RSV
and rechallenged at 12 wks of age, inflammatory cell
recruitment was enhanced (including Th2 cells and eosi-
nophils) [12]. Their data suggested that neonatal exposure
to RSV exacerbated subsequent disease upon rechallenge
in the adult. [12]. More recently, Dakhama and colleagues
infected 1-wk old or 3-wk old mice with RSV, and they
found that both primary infections led to increased lung
resistance, mucus hyperproduction and inflammation
along with increased lymphocytes in the lung. [13]. Fur-
thermore, they demonstrated that the BAL fluid from mice
infected with RSV at 1 wk of age had reduced levels of IFN-
γ and elevated levels of IL-13 compared to mice initially
infected at 3 wks of age. This data indicated that a Th2
polarized response occurred in mice infected with RSV at
1 wk of age, while a Th1-biased response occurred in the
mice infected with RSV at 3 wks of age. When rechal-
lenged with RSV 5 weeks later (i.e., infection at 1 wk and
reinfection at 6 wks of age), these mice displayed exacer-
bated disease as indicated by enhanced pulmonary resist-
ance, mucus hyperproduction, eosinophilia, and elevated
levels of Th2 cytokines. In contrast, initial infection of
mice at 3 wks of age resulted in protection upon RSV
rechallenge as indicated by the abolished lung resistance
and enhanced viral clearance at rechallenge [13]. These
experiments indicate that age at initial RSV infection influ-
ences the subsequent immune and physiologic response
upon re-exposure to RSV.
We hypothesized that neonatal exposure to RSV plays a
critical role in the pathophysiological response to subse-
quent allergen exposure and the development of allergic
asthma. To investigate whether neonatal exposure to RSV
influences airway hyperreactivity (AHR), mice were
infected with RSV at 1 wk of age. At 6 wks of age, these
mice were then sensitized and challenged with ovalbumin
(Ova). Pulmonary function, histopathology, and bron-
choalveolar lavage fluid (BALF) cellularity and cytokine
production were examined 24 hours after the last Ova
challenge. The results were compared to sham infected
and/or saline exposed mice and demonstrated that neona-
tal exposure to RSV resulted in elevated and prolonged
AHR, chronic pulmonary inflammation, and subepithe-
lial fibrosis in adult mice. These pathophysiological end-
points were most severe when neonatal RSV infection was
followed by allergen sensitization and challenge. These
studies demonstrate the ability of neonatal exposures to
chronically alter lung function and the importance of pre-
venting RSV exposure during infancy.
Methods
The study protocol is outlined in Figure 1. Mice were
divided into four groups. RSS mice were infected with RSV
and mock-sensitized and challenged. OVA mice were
mock-infected then Ova sensitized and challenged. ROO
mice were infected with RSV and then Ova-sensitized and
challenged. As the control group, SAL mice were mock
infected, mock-sensitized and challenged. Data were col-
lected on protocol days 0, 4, 69 and 96.
Mice
BALB/c breeders were purchased from the Division of Lab-
oratory Animal Medicine (School of Veterinary Medicine,
Louisiana State University) and seven day old pups were
obtained by time-mating. All mice were maintained in
ventilated micro-isolator cages housed in a specific patho-
gen-free animal facility. Sentinel mice within this animal
colony were negative for antibodies to viral and other
known mouse pathogens. All animal protocols were pre-
pared in accordance with the Guide for the Care and Use
of Laboratory Animals (National Research Council, 1996)
and approved by the Institutional Animal Care and Use
Committee at Louisiana State University.
Infection of mice with RSV and assessment of viral titers
Seven day old mice (protocol day 0; Figure 1) were
infected intranasally (i.n.) with 2 × 105 TCID50 RSV/g
body weight (RSV A-2, Advanced Biotechnologies Incor-
porated, Columbia, MD) or culture media alone (OVA
group). Four days post-infection, viral titer of whole lungRespiratory Research 2006, 7:107 http://respiratory-research.com/content/7/1/107
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homogenates was determined using the TCID50 method
of Spearman-Kärber [14,15].
Ovalbumin sensitization and challenge
Mice were sensitized and challenged with chicken ovalbu-
min (grade V; Sigma, St. Louis, MO) as previously
described [16]. Mice were intraperitoneally (i.p.) injected
with 20 µg Ova complexed with 2 mg Imject Alum (Al
[OH]3/Mg [OH]2; Pierce, Rockford, IL) or Sal (RSS and
SAL group) on protocol days 41 and 55 (Figure 1) and
subsequently challenged with aerosolized 1% Ova (in iso-
tonic Sal) or Sal (RSS and SAL group) using an ultrasonic
nebulizer (PariNeb Pro Nebulizer) on protocol days 65–
67 (Figure 1).
Assessment of pulmonary function
A) Lung resistance in response to methacholine
On protocol day 69, lung resistance to increasing doses of
methacholine (MeCh, Sigma; 0, 6.25, 12.5, and 25 mg/ml
in isotonic saline) was assessed using the forced oscilla-
tion technique as previously described [16]. Anesthetized
animals were mechanically ventilated with a tidal volume
of 10 ml/kg and a frequency of 2.5 Hz using a computer-
controlled piston ventilator (FlexiVent, SCIREQ; Mon-
treal, Canada). Resistance data were collected using single
compartment model and plotted as the percent change
from the 0 mg/ml MeCh dose.
B) Airway hyperreactivity in response to methacholine
Airway hyperresponsiveness to MeCh (Sigma; 0, 6.25,
12.5, 25 and 50 mg/ml in isotonic saline) was assessed by
whole body plethysmography (Buxco Electronics, Troy,
NY and EMKA Technologies, Falls Church, VA) as
described previously [16]. Mice were exposed to aero-
solized MeCh for 3 minutes at each dose and enhanced
pause (Penh) was recorded for 3 minutes and averaged for
each dose. Penh data were plotted as percent change from
saline per dose.
Determination of Bbronchoalveolar Lavage Fluid 
cellularity
On protocol day 69, bronchoalveolar lavage fluid (BALF)
was isolated in 1 ml of PBS containing 2% heat-inacti-
vated FBS. Total BAL cellularity was determined with the
use of a hemocytometer. Cytospin slides were fixed and
stained using the Diff-Quick kit (IMEB, Chicago, IL), and
differential cell counts by two unbiased observers were
obtained using standard morphological criteria to classify
individual leukocyte populations. Three mice from each
group were used for these analyses, and 200–300 cells
were counted per cytospin preparation.
Pulmonary histopathology
On protocol day 69, lungs were inflated with 1 ml of 4%
paraformaldehyde. The lungs were then excised and fixed
in 4% paraformaldehyde for 24 hours at 4°C. These tis-
sues were then embedded in paraffin, cut in 4 µm frontal
sections and stained with hematoxylin and eosin (H&E),
periodic acid-Schiff (PAS) to show mucus production in
airway goblet cells, or Masson's trichrome (MT) to indi-
cate airway collagen deposition. Scores were assigned to
these histological endpoints by two independent observ-
ers and were recorded on a scale of 0–3.
Cytokine level in BAL fluid
IL-2, IL-4, IL-5, IFN-γ, and TNF-α levels in the BALF were
examined using the Mouse Th1/Th2 Cytokine Cytometric
Bead Array Kit (BD Biosciences, San Diego, CA) as per the
manufacturer's instructions. Data were acquired with a
BD FACScan™ flow cytometer. Data analyses were per-
formed using the BD Cytometric Bead Array Software to
generate standard curves for each cytokine and to deter-
Schematic of study protocol and exposure groups Figure 1
Schematic of study protocol and exposure groups. Neonatal mice (7 days of age) were infected with RSV (2 × 105 
TCID50/g body weight; RSS, ROO groups). On protocol days 41 and 55, mice were injected i.p. with ovalbumin complexed to 
Imject Alum (OVA and ROO groups) or with isotonic saline (SAL and RSS groups). These mice were then exposed to aero-
solized ovalbumin or saline for 20 minutes on protocol days 65, 66, and 67. n = 8/group.Respiratory Research 2006, 7:107 http://respiratory-research.com/content/7/1/107
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mine sample cytokine levels. IL-13 levels in BALF were
determined using the Mouse IL-13 ELISA Ready-SET-Go
kit (eBioscience, San Diego, CA). The sensitivity for each
cytokine is as follows: 5.0 pg/ml for IL-2, IL-4 and IL-5; 2.5
pg/ml for IFN-γ, 6.3 pg/ml for TNF-α and 30 pg/ml for IL-
13.
Statistical analysis
Data are presented as mean ± SEM and were obtained
from experiments with n = 8 for whole body plethysmog-
raphy analysis of AHR, n = 4–5 for invasive measurements
of pulmonary mechanics, and n = 3 for BAL cellularity,
cytokine assays, pulmonary viral titers and histology. For
AHR, lung resistance and BAL cellularity, differences
between groups were evaluated by means of two-way
ANOVA using GraphPad Prism (GraphPad Software Inc,
San Diago, CA). Bonferroni post-tests were performed to
compare between pairs of groups. A one-way ANOVA was
used to compare the mean cytokine levels among the var-
ious groups followed by the Tukey-Kramer multiple com-
parisons tests for significance between the groups. This
was repeated for each individual cytokine. Differences
between means were considered significant when p <
0.05.
Results
Reduced pulmonary function was observed in mice 
infected with RSV as neonates
To determine if neonatal exposure to RSV is sufficient to
induce long-term pulmonary dysfunction, mice were
infected with RSV (2 × 105 TCID/g body weight) at seven
days of age and then allowed to mature to adults (Figure
1). Four days post-infection, we assessed pulmonary viral
titers for Sham and RSV infected mice. As expected, mice
from the Sham infected groups displayed no evidence of
viral replication. The mean viral titer in the lungs of neo-
natal mice exposed to RSV alone (RSS and ROO) was 2.67
± 1.29 × 106 TCID50/g lung tissue.
After maturation, subsets of mice were then sensitized
(protocol days 41 and 55) and challenged (protocol days
65, 66, and 67) with ovalbumin – OVA and ROO groups.
All other mice received saline – RSS and SAL groups. AHR
was assessed on protocol day 69 and 96 (2.5 and 3.5
months after infection). We observed no significant differ-
ence in baseline airway resistance between the RSV
infected (mean ± SEM; 0.52 ± 0.01 cm H2O.s/mL) or
sham infected mice (0.64 ± 0.06). For ease of comparison
among all groups, lung resistance data was normalized by
plotting the percentage difference from baseline (percent
difference = 100 * ((value-baseline)/baseline). Lung
resistance in response to increasing concentrations of
inhaled MeCh was significantly greater in RSV infected
neonates (RSS; 121.79 ± 10.20) than control mice (SAL;
89.05 ± 6.51) at 25 mg/ml MeCh (1.4 times, p < 0.01)
(Figure 2A). Neonatal RSV infection followed by exposure
to Ova (ROO) resulted in the highest lung resistance
among the four groups (392.50 ± 32.84). This increased
airway resistance was greater than could be accounted for
by Ova exposure alone (OVA; 264.63 ± 23.01). Thus, neo-
natal exposure to RSV infection appears to predispose
adults to the development of airway responsiveness to
subsequent allergen exposure.
To investigate the long-term influence of neonatal expo-
sure to RSV, AHR was assessed by whole body plethys-
mography on protocol day 96 (103 days of age). Penh
data was normalized and the percentage difference from
baseline was plotted. Mice in the RSS group continued to
demonstrate reduced airway function 3 months post-
infection as evidenced by a significantly increased Penh
compared to SAL mice at 25 and 50 mg/ml MeCh (314.30
± 40.40 vs 100.00 ± 40.80 at 25 mg/ml; 714.30 ± 101.00
vs 311.10 ± 58.80 at 50 mg/ml; p < 0.001 and p < 0.001,
respectively) (Figure 2B). These data demonstrate that
neonatal infection with RSV results in the development of
chronic AHR, and furthermore, that airway function is fur-
ther diminished due to an allergic phenotype.
Neonatal RSV infection predisposes mice to chronic 
pulmonary inflammation indicated in BALF cellularity
To evaluate the pulmonary immune response to RSV, BAL
fluid was isolated, total cells recovered were counted, and
the cellular composition of BALF was determined using
morphological criteria. RSV and/or Ova exposed mice
recruited significantly more leukocytes than control mice
(SAL group, p < 0.001) (Figure 3). However, there was no
significant difference in the total number of recovered
cells among the RSS, OVA, and ROO groups. Interestingly,
BALF cellularity was elevated in mice exposed to RSV as
neonates (RSS) on protocol day 69. Upon allergen sensi-
tization and challenge, total BALF cellularity was not sig-
nificantly altered compared to RSS although the cell
populations were changed. Neonatal RSV infection
resulted in a predominantly monocyte/macrophage pul-
monary infiltrate and these cells seemed to account for the
elevation in the total number of recovered cells. In con-
trast, Ova exposure, in the absence (OVA) or presence of
neonatal RSV (ROO) infection, resulted in a significant
BALF eosinophilia (compared to control SAL group, p <
0.001). Concomitant with the observed increase in BALF
eosinophil numbers in the OVA and ROO groups was a
decrease in BALF macrophage numbers.
Cytokine levels in BAL fluid is altered in mice exposed to 
RSV and/or Ova
Cytokine levels in BAL fluid were examined to study the
Th1/Th2 polarization in RSV and/or Ova exposed mice.
As shown in Figure 4A, we assayed cytokine levels in BALF
five hours post-infection, and observed greatly elevatedRespiratory Research 2006, 7:107 http://respiratory-research.com/content/7/1/107
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TNF-α (21.4 times, p < 0.001) in RSV infected neonates.
In addition, Th2 cytokines (IL-4 and IL-5) along with IL-2
were detected in BALF of neonatal infected mice whereas
no IL-4, IL-5, or IL-2 was detected in control mice (SAL
group). TNF-α levels declined by protocol day 69 in mice
infected with RSV as neonates, but was elevated in RSV
infected and Ova exposed mice (ROO group, Figure 4B).
Intriguingly, IL-13 levels were elevated in RSS mice at pro-
tocol day 69 compared to SAL mice (p < 0.001). Mice
exposed to RSV and Ova (ROO group) showed increased
Th2 cytokines (IL-5 and IL-13) compared to SAL group. In
addition, IL-13 levels in ROO mice were significantly ele-
vated compared to the animals exposed to Ova alone
(OVA group; p < 0.01). Neonatal infection with RSV also
resulted in increased levels of TGF-β1 protein in the lungs
4d post-infection (RSS: 29.8 ± 0.45 ng/g lung tissue) com-
pared to mice exposed to Sal alone (22.1 ± 0.39 ng/g lung
tissue).
Enhanced pulmonary histopathology in mice exposed to 
RSV and/or Ova
Airway inflammation, mucus hyperproduction, and colla-
gen deposition in the subepithelial reticular layer of the
airway were observed in mice exposed to RSV and/or Ova
(Figure 5A: inflammation; Figure 5B: mucus production;
Figure 5C: collagen deposition). Mice exposed to both
RSV and Ova demonstrated the largest amount of inflam-
mation, mucus production, and collagen deposition (Fig-
ure 5D), and this was consistent with the greatest lung
resistance and airway hypersensitivity (Figure 2). In addi-
tion, tremendous perivascular inflammation was
observed in both groups of mice exposed to Ova (i.e.,
OVA and ROO mice; Figure 5A). Mice infected with RSV
as neonates displayed chronic (69d post infection)
inflammation, mucus production and collagen deposi-
tion compared to control mice (SAL group), which also
correlated to enhanced lung resistance and airway hyper-
Airway hyperreactivity in RSV and/or Ova exposed mice Figure 2
Airway hyperreactivity in RSV and/or Ova exposed mice. Mice were infected with RSV as neonates (RSS) and exposed 
to Ova 5 wks later (ROO). Controls were sham infected and exposed to Saline (SAL) or Ova (OVA). A. Lung resistance of 
each group is plotted as a function of increasing doses of inhaled MeCh, using single compartment model. B. Penh is plotted as 
a function of increasing dose of inhaled MeCh (0 to 50 mg/ml). Data were collected on protocol days 69 (A) or 96 (B), normal-
ized to saline airway responses as described in methods, and expressed as mean ± SEM. n = 4–5/group. ***p < 0.001; **p < 
0.01.Respiratory Research 2006, 7:107 http://respiratory-research.com/content/7/1/107
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sensitivity in the RSS group (Figure 2). Increased peri-
bronchial and perivascular collagen deposition and
peribronchial smooth muscle deposition indicated that
airway remodeling occurred in mice exposed to RSV and/
or Ova (Figure 5B), and that neonatal RSV infection alone
was sufficient to induce airway remodeling.
Discussion
In the present study, we have shown that neonatal expo-
sure to RSV alone induced long-term airway hyperrespon-
siveness and pulmonary resistance in mice. This result was
correlated with peribronchial inflammation, increased
BALF cellularity, increased mucus production, and airway
remodeling. Elevations in TNF-α and Th2 cytokines (IL-4
and IL-5) were observed in BALF immediately following
neonatal RSV infection. Once these mice had matured
(protocol day 69), only IL-13 remained elevated in the
BALF. Neonatal RSV infection followed by adult exposure
to allergen resulted in significantly higher lung resistance,
along with increased total cellularity, eosinophilia, and
increased TNF-α and Th2 cytokines (IL-5 and IL-13) in
BALF. In addition, TNF-α and IL-13 were significantly
higher compared to mice exposed to Ova alone. The most
severe lung histopathology was observed in mice exposed
to both RSV and Ova, as indicated by severe peribronchial
and perivascular inflammation, mucus production, and
collagen deposition. Collectively, these data suggest that
neonatal RSV infection influences adult immune response
to allergen (Ova) and exacerbates allergic pathophysiol-
ogy in mice long after viral titers are no longer detectable.
In contrast to previously published studies analyzing the
effect of RSV infection on allergen exposure in adult mice.
[17], the present study investigated the influence of neo-
natal RSV infection on adult allergen sensitization. Neo-
natal infection with RSV alone was sufficient to induce
long-term pulmonary dysfunction and inflammation.
Similarly, neonatal infection of brown Norway rats with
parainfluenza type 1 (Sendai) virus also led to increases in
pulmonary resistance and hyperresponsiveness to metha-
choline up to 65d after infection [18]. As in our model,
persistent airway dysfunction following neonatal infec-
tion with Sendai virus correlated with increased peribron-
chial fibrosis and pulmonary inflammation. [19].
Furthermore, both models (i.e., neonatal RSV infection
and neonatal Sendai virus infection) resulted in signifi-
cantly increased mRNA [19] and protein levels for TGF-β1.
Although numerous cytokines may contribute to airway
remodeling, the elevation of TGF-β1, a fibrogenic
cytokine, in both neonatal viral infection models prior to
the development of fibrosis suggests a role this cytokine in
the regulation of viral-induced airway remodeling
observed in neonates.
More importantly, neonatal infection with RSV predis-
posed mice to the development of enhanced AHR and
inflammation after allergen exposure. In contrast, adult
RSV infection prior to allergen exposure seemed to assert
a "protective" response as evidenced by significantly
decreased allergen induced pulmonary resistance, tissue
eosinophilia, and IL-13 levels [20]. Our data presented
here and elsewhere [16] extend these findings and, more
importantly, demonstrate that the age at initial RSV infec-
tion also determines whether RSV infection will exacer-
bate or prevent subsequent allergic inflammation.
A more recent study using neonatal RSV infection fol-
lowed by subsequent reinfection of adults with RSV dem-
onstrated that early RSV infection also exacerbates RSV
induced diseases in the adult [13]. Interestingly, if the pri-
mary RSV infection occurred at 3 wks of age, a protective
effect upon secondary infection was observed similar to
that reported by Peebles and colleagues [17]. Dakhama
and colleagues further established that enhancement of
AHR, pulmonary eosinophilia, and mucus hyperproduc-
tion during reinfection were dependent on IL-13 [13]. We
BAL cellularity in RSV and/or Ova exposed mice Figure 3
BAL cellularity in RSV and/or Ova exposed mice. 
Bronchoalveolar lavage fluid was isolated on protocol day 69. 
RSV and/or Ova induced significant increase in total BAL cel-
lularity. In mice exposed to RSV as neonates (RSS), this 
increase correlated with elevated levels of macrophages; 
whereas, in mice exposed to Ova (ROO and Ova), this 
increase correlated to elevation in eosinophil numbers. Data 
are expressed as means ± SEM, n = 3/group. ***p < 0.001Respiratory Research 2006, 7:107 http://respiratory-research.com/content/7/1/107
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demonstrated that neonatal RSV infection alone leads to
elevated levels of IL-13 in the lung and that exposure to
allergen significantly increases IL-13 levels over RSV expo-
sure alone. IL-13 has emerged as a major regulatory mol-
ecule involved in mucus hyperproduction and allergen
induced AHR [21-23]. It is entirely possible that the long-
term AHR, pulmonary inflammation, and mucus produc-
tion observed in our neonatal RSV model is due to high
levels of IL-13. In fact, elevated levels of IL-13 were
observed in whole lung homogenates as early as 5 hours
post-infection (data not shown) and were again observed
in adult lungs on protocol day 69 suggesting that IL-13 is
being chronically produced. Although the exact cellular
source of IL-13 in this neonatal model of RSV infection is
currently unknown, previous studies have demonstrated
that epithelial cells and/or macrophages infected by RSV
are a significant source of IL-13 and are capable of produc-
ing this cytokine for months after the initial infection.
[24]. We are currently investigating this possibility.
In our study, TNF-α was significantly elevated in the BALF
shortly after infection with RSV. TNF-α is an important
cytokine for innate immune responses and a central regu-
lator of inflammatory processes, through binding to dis-
tinct membrane receptors, referred to as p55 or TNFR1
and p75 or TNFR2 [25]. TNF-α is likely a central mediator
of airway inflammation and AHR in asthma, regulating
inflammatory cell infiltration, locally enhancing vascular
permeability, and inducing the release of the chemokines.
Ultimately, this will lead to chronic inflammation and
irreversible airway remodeling. Recently, depletion stud-
ies using monoclonal antibody therapy for TNF-α have
shown promising effects in viral-specific lung immunopa-
thology. [26], rheumatoid arthritis [27] and inflammatory
Cytokine levels in the BAL fluid of mice exposed to RSV and/or Ova Figure 4
Cytokine levels in the BAL fluid of mice exposed to RSV and/or Ova. Bronchoalveolar lavage fluid was isolated 5 hr 
post-infection with RSV (A) or on protocol day 69 (B). A. Elevated levels of TNF-α, IL-5, IL-4, and IL-2 were observed as early 
as 5 hrs post-infection, although significance over SAL controls was observed only for TNF-α. IL-2, IL-4 and IL-5 were below 
the limit of detection in the SAL mice. B. IL-13 was significantly elevated in RSS mice; while TNF-α, IL-5, and IL-13 were signif-
icantly enhanced in mice exposed to RSV and Ova (ROO). IL-13 was below the limit of detection in control animals (SAL). 
Data are expressed as means ± SEM, n = 3/group. ***p < 0.001, **p < 0.01, and *p < 0.05.Respiratory Research 2006, 7:107 http://respiratory-research.com/content/7/1/107
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bowel disease [28]. Moreover, a soluble TNF receptor
fusion protein, etanercept, has proven efficacious in treat-
ing juvenile rheumatoid arthritis in patients as young as 4
[27]. In viral models, TNF-α depletion reduced recruit-
ment of inflammatory cells, reduced type 1 and type 2
cytokines in BALF, and decreased pulmonary pathology
without inhibiting viral clearance [26,29]. Although the
precise mechanism by which TNF-α leads to the pathol-
ogy in lungs after RSV infection remains unknown, our
data and these previous studies suggest a key role for TNF-
α in chronic inflammation in the lung and subsequent
airway remodeling associated with asthma.
Several studies along with our present data have estab-
lished the correlation of severe RSV infection followed by
allergen exposure and the development of allergic inflam-
Lung histopathology of mice exposed to RSV and/or Ova Figure 5
Lung histopathology of mice exposed to RSV and/or Ova. Lung tissue sections were obtained from mice on protocol 
day 69. Tissue sections were stained with H&E (A), PAS (B), and MT (C). A. Lung inflammation, B. mucus (purple) hyperpro-
duction, and C. collagen (blue) deposition were observed in mice exposed to RSV and/or Ova. D. Scores were assigned to 
these histological endpoints by two independent observers and were recorded on a scale of 0–4. Increased deposition of peri-
bronchial and perivascular collagen was observed in the subepithelial reticular layer of the airways in RSS, OVA and ROO mice. 
In all cases, neonatal RSV infection (RSS) induced persistent lung pathologies including increased peribronchial inflammation, 
mucus production, and subepithelial fibrosis were exacerbated by subsequent exposure to allergen (ROO). n = 3/group. ***p < 
0.001, *p < 0.05.Respiratory Research 2006, 7:107 http://respiratory-research.com/content/7/1/107
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matory disease (i.e., asthma) in mice. Although the mech-
anism by which the exposure causes asthma and the
importance of such exposures in humans need to be fur-
ther elucidated, our current and previously published data
[16] demonstrate that the initial age of the RSV infection
is capable of altering adult pulmonary function and exac-
erbating pulmonary immunopathology when followed
by subsequent allergen exposure. Furthermore, enhanced
AHR correlated with chronic pulmonary inflammation,
upregulation of the Th2 cytokine, IL-13, and subepithelial
fibrosis of the bronchial airways. Increases in TNF-α
within 5 hours of RSV infection in our mouse model also
suggest a role for this cytokine in the immunopathology
of RSV-induced wheeze and asthma development in
humans.
Conclusion
We have demonstrated that neonatal infection with RSV
in mice leads to reduced lung function, which is associ-
ated with chronic inflammation, increased mucus pro-
duction, and airway remodeling in the lung. In addition,
RSV infection in neonates predisposes the adult to
develop enhanced airway responses upon allergen expo-
sure. The upregulation of TNF-α and IL-13 suggests that
these cytokines may play a key role in mediating this proc-
ess and highlights the importance of these cytokines as
therapeutic targets for RSV induced asthma.
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